홈 > 시장보고서 > 의약품

시장보고서

상품코드

1747314

2세대 항정신병제 시장 : 적응증별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별

Second Generation Antipsychotics Market, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

발행일: 2025년 05월 | 리서치사:

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 2세대 항정신병제 시장은 2025년에는 102억 5,000만 달러, 2032년에는 156억 7,000만 달러에 이를 것으로 예측되며, 2025-2032년 CAGR 6.25%를 보일 것으로 예측됩니다.

보고서 범위		보고서 상세
기준 연도	2024년	2025년 시장 규모	102억 5,000만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간(2025-2032년) CAGR	6.25%	2032년 가치 예측	156억 7,000만 달러

세계 2세대 항정신병제 시장은 정신질환의 유병률 증가와 효과적인 치료에 대한 수요 증가로 인해 최근 몇 년 동안 괄목할 만한 성장세를 보이고 있습니다. 비정형 항정신병제로도 알려진 2세대 항정신병제은 정신분열증, 양극성 장애, 주요우울장애 등 다양한 정신질환을 관리하기 위한 대안으로 떠오르고 있습니다. 이들 약물은 1세대 항정신병 약물에 비해 효과 향상, 추체외로계 부작용 감소, 내약성 개선 등 몇 가지 장점이 있습니다. 2세대 항정신병제 시장은 정신건강에 대한 인식 제고, 신규 제제 개발, 적응증 확대 등에 힘입어 향후에도 성장세를 이어갈 것으로 예측됩니다.

시장 역학:.

세계 2세대 항정신병제 시장은 노령 인구 증가와 정신 건강에 대한 인식 증가 등 여러 요인에 의해 주도되고 있습니다. 세계보건기구(WHO)의 추산에 따르면, 전 세계적으로 약 4억 5,000만 명이 정신질환을 앓고 있어 효과적인 치료에 대한 수요가 크게 증가하고 있습니다. 또한, 2세대 항정신병제의 장기지속형 주사제제의 개발로 환자의 순응도와 편의성이 향상되어 시장 성장을 더욱 촉진하고 있습니다. 그러나 이들 약물의 고가, 부작용 가능성, 정신질환에 대한 편견 등 시장 성장 억제요인도 존재합니다. 또한, 주요 약물의 특허 만료와 제네릭 의약품의 출현도 시장 역학에 영향을 미칠 수 있습니다. 하지만 개인 맞춤형 의료에 대한 관심 증가, 새로운 약물 전달 시스템 시장 개척, 다른 정신질환 치료에서 2세대 항정신병제의 용도 확대 등으로 인해 시장에는 큰 성장 기회가 존재합니다.

본 조사의 주요 특징

세계의 2세대 항정신병제 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 정리하여 전해드립니다.
또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 2세대 항정신병제 시장의 주요 기업 프로파일을 수록했습니다.
이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
세계 2세대 항정신병 약물 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 2세대 항정신병제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 10.25 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.25%	2032 Value Projection:	USD 15.67 Bn

The global second generation antipsychotics market has witnessed significant growth in recent years, driven by the increasing prevalence of mental health disorders and the rising demand for effective treatments. Second generation antipsychotics, also known as atypical antipsychotics, have emerged as a preferred choice for the management of various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. These medications offer several advantages over first generation antipsychotics, such as improved efficacy, reduced extrapyramidal side effects, and better tolerability. The market for second generation antipsychotics is expected to continue its upward trajectory, fueled by the growing awareness about mental health, the development of novel formulations, and the expanding indications for these drugs.

Market Dynamic:

The global second generation antipsychotics market is driven by several factors, including the growing geriatric population, and the increasing awareness about mental health. The World Health Organization estimates that around 450 million people globally suffer from mental health disorders, creating a significant demand for effective treatments. Additionally, the development of long-acting injectable formulations of second generation antipsychotics has improved patient compliance and convenience, further driving market growth. However, the market also faces certain restraints, such as the high cost of these medications, the potential for side effects, and the stigma associated with mental health disorders. Patent expiration of key drugs and the emergence of generic alternatives may also impact the market dynamics. Nevertheless, the market presents substantial opportunities for growth, driven by the increasing focus on personalized medicine, the development of novel drug delivery systems, and the expanding applications of second generation antipsychotics in the treatment of other psychiatric disorders.

Key Features of the Study:

This report provides in-depth analysis of the global second generation antipsychotics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global second generation antipsychotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Lundbeck, Sanofi, Merck & Co., AbbVie, Takeda Pharmaceutical, Amgen, GlaxoSmithKline, and Alkermes
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global second generation antipsychotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global second generation antipsychotics market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
- Autism Spectrum Disorder
- Other Indications
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Asenapine
- Clozapine
- Paliperidone
- Brexpiprazole
- Lurasidone
- Others
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Johnson & Johnson
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Otsuka Pharmaceutical
- Lundbeck
- Sanofi
- Merck & Co.
- AbbVie
- Takeda Pharmaceutical
- Amgen
- GlaxoSmithKline
- Alkermes

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Second Generation Antipsychotics Market, By Indication
- Global Second Generation Antipsychotics Market, By Drug Class
- Global Second Generation Antipsychotics Market, By Route of Administration
- Global Second Generation Antipsychotics Market, By Distribution Channel
- Global Second Generation Antipsychotics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Second Generation Antipsychotics Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Schizophrenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Major Depressive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autism Spectrum Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Second Generation Antipsychotics Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Risperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Quetiapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Olanzapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Aripiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Asenapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Clozapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Paliperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Brexpiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lurasidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Second Generation Antipsychotics Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Second Generation Antipsychotics Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Second Generation Antipsychotics Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alkermes
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,676,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,385,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,837,000

※ 부가세 별도

검색

F A Q

2세대 항정신병제 시장 : 적응증별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별

Second Generation Antipsychotics Market, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

본 조사의 주요 특징

목차

제1장 조사 목적과 전제조건

제2장 시장 전망

제3장 시장 역학, 규제, 동향 분석

제4장 세계의 2세대 항정신병제 시장, 적응증별, 2020년-2032년

제5장 세계의 2세대 항정신병제 시장, 약제 클래스별, 2020년-2032년

제6장 세계의 2세대 항정신병제 시장, 투여 경로별, 2020년-2032년

제7장 세계의 2세대 항정신병제 시장, 유통 채널별, 2020년-2032년

제8장 세계의 2세대 항정신병제 시장, 지역별, 2020년-2032년

제9장 경쟁 구도

제10장 애널리스트 추천 사항

제11장 참고 문헌과 조사 방법